AI scans could spot chemo failures early in pancreatic cancer
NCT ID NCT07243288
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether analyzing CT scans with a computer technique called radiomics can predict which patients with advanced pancreatic cancer will not respond to chemotherapy. Researchers will study 400 patients and track survival over time. The goal is to find early signs that treatment isn't working, so doctors can adjust care sooner.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors identify early which patients are not benefiting from chemotherapy, allowing them to switch treatments sooner.
- What could go wrong
- This is an observational study, not testing a new treatment. The radiomics method is still experimental and may not prove reliable enough for routine use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MESH TERM-PANCREATIC CANCER, ADULT) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Cochin
Paris, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- MRI might reveal hidden pancreatic risks in obesity
- Can a new PET tracer light up hidden cancers?